EGFR and prostate cancer: Thus, FTase inhibitors are antitumor drugs that target the Ras protein.242 It has been found that the FTase inhibitors manumycin-A and Tipifarnib lead to the inhibition of TDSEV secretion by prostate cancer cells by selectively affecting the RAS/RAF/ERK pathway.243,244 Recently, Sasabe et al. found that EGFR inhibitors inhibit the malignant potential of oral squamous cell carcinoma (OSCC) cells by directly inhibiting EGFR downstream signaling pathways as well as by inhibiting the uptake of TDSEVs through macropinocytosis,245 which confirms that anti-EGFR agents may be TDSEV inhibitors.